Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Internal medicine

• Publication date

  2003-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2169/INTERNALMEDICINE.42.955PMID 14606707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of i.v. and oral 1,25-dihydroxy-22-oxavitamin D(3) on secondary hyperparathyroidism in dogs with chronic renal failure.

  2002cited by this paper
• 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.

  1999cited by this paper
• Effects of new analogues of vitamin D on bone cells: implications for treatment of uremic bone disease.

  1999cited by this paper
• Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.

  1996cited by this paper
• Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.

  1994cited by this paper
• Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients.

  1994cited by this paper
• Effect of 22-oxa-calcitriol on calcium metabolism in rats with severe secondary hyperparathyroidism.

  1993cited by this paper
• Differential effects of 1,25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism.

  1993cited by this paper
• Recent progress in management of secondary hyperparathyroidism of chronic renal failure.

  1993cited by this paper
• Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism.

  1992cited by this paper
• Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover.

  1991cited by this paper
• The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.

  1991cited by this paper
• Regulation of parathyroid hormone synthesis in chronic renal failure in rats.

  1991cited by this paper
• Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis.

  1990cited by this paper
• The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

  1989cited by this paper
• The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.

  1989cited by this paper
• Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

  1989cited by this paper
• Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis.

  1989cited by this paper
• Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton A trial of the development of vitamin D compounds which exhibit potent differentiation‐inducing activity without inducing hypercalcemia

  1987cited by this paper
• Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis.

  1984cited by this paper
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

  1984cited by this paper

• Clinical Features and Hyperplastic Patterns of Parathyroid Glands in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism Refractory to Maxacalcitol Treatment and Required Parathyroidectomy

  2007cites this paper
• Is the Volume of the Parathyroid Gland a Predictor of Maxacalcitol Response in Advanced Secondary Hyperparathyroidism?

  2006cites this paper
• Pretreatment plasma intact parathyroid hormone and serum calcium levels, but not serum phosphate levels, predict the response to maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism

  2005cites this paper
• Maxacalcitol is a Possible Less Phosphatemic Vitamin D Analog

  2005cites this paper
• Which vitamin D derivative to prescribe for renal patients

  2005cites this paper
• New vitamin D analogues for osteodystrophy in chronic kidney disease

  2004cites this paper